Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JBM (Healthcare)HKSE:02161 86 Days Inventory is 81.43 as of Mar. 2026, which is 5% below its 10-year median of 85.95. GuruFocus rates HKSE:02161 with a GF Score™ of 86/100 and a GF Value™ of HK$2.08 (Fairly Valued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, JBM (Healthcare) ranks better than 85.05% on this metric.
The historical rank and industry rank for JBM (Healthcare)'s Days Inventory or its related term are showing as below:
HKSE:02161'
s Days Inventory Range Over the Past 10 Years
Min: 59.38 Med: 85.95 Max: 102.67
Current: 83.9
During the past 9 years, JBM (Healthcare)'s highest Days Inventory was 102.67. The lowest was 59.38. And the median was 85.95.
HKSE:02161's Days Inventory is ranked better than 85.05% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs HKSE:02161: 83.90
JBM (Healthcare)'s Days Inventory
declined
from Mar. 2025 (91.94) to Mar. 2026 (81.43).
Inventory Turnover measures how fast the company turns over its inventory within a year.
JBM (Healthcare)'s Inventory Turnover for the
six
months ended in Mar. 2026 was 2.24.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
JBM (Healthcare)'s Inventory-to-Revenue for the
six
months ended in Mar. 2026 was 0.21.
JBM (Healthcare) (HKSE:02161) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
JBM (Healthcare)'s Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
JBM (Healthcare)'s Inventory to Revenue for the
six
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
JBM (Healthcare) Days Inventory Related Terms
JBM (Healthcare) Days Inventory Historical Data
* Premium members only.
The historical data trend for JBM (Healthcare)'s Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JBM (Healthcare) Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s Days Inventory distribution charts can be found below:
* The bar in red indicates where JBM (Healthcare)'s Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JBM (Healthcare) (HKSE:02161) has a Days Inventory of 81.43 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on JBM (Healthcare) and its competitors. This is near median its historical median of 85.95. Over the past decade, JBM (Healthcare)'s Days Inventory has ranged from 59.38 to 102.67. According to the industry distribution chart, JBM (Healthcare) ranks #138 out of 923 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is JBM (Healthcare)'s Days Inventory too high?
JBM (Healthcare)'s current Days Inventory of 81.43 is near median its 10-year median of 85.95. Over the past 10 years, this metric has ranged from a low of 59.38 to a high of 102.67. The Drug Manufacturers industry median Days Inventory is 164.87. JBM (Healthcare)'s value of 81.43 is 50.6% below this industry median. Based on the distribution chart, JBM (Healthcare) ranks #138 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JBM (Healthcare) has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JBM (Healthcare)'s Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JBM (Healthcare) ranks #138 out of 923 companies for Days Inventory. This places JBM (Healthcare) in the top 15% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.87. JBM (Healthcare)'s value of 81.43 is 50.6% below this benchmark. Historically, JBM (Healthcare)'s own Days Inventory has ranged from 59.38 to 102.67 over the past decade. While the company's 10-year median is 85.95 vs. the industry median of 164.87, JBM (Healthcare) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JBM (Healthcare)'s current Days Inventory of 81.43 is 50.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on JBM (Healthcare) and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JBM (Healthcare)'s current Days Inventory is 81.43, which is near median its own 10-year median of 85.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JBM (Healthcare) stock overvalued right now?
Based on GuruFocus' analysis, JBM (Healthcare) (HKSE:02161) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.08, compared to a current price of HK$1.92 — trading 7.7% below its estimated fair value. The current Days Inventory is 81.43, which is near median its 10-year median of 85.95 and 50.6% below the Drug Manufacturers industry median of 164.87. JBM (Healthcare)'s overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For JBM (Healthcare) (HKSE:02161), the current Days Inventory is 81.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?
Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued.
The current stock price of HK$1.92 is trading 7.7% below its estimated GF Value™ of HK$2.08.
GuruFocus considers JBM (Healthcare) to be Fairly Valued.
Key valuation signals for HKSE:02161:
Days Inventory: 81.43 (near median its 10-year median of 85.95)
GF Value™: HK$2.08 vs. price of HK$1.92 (7.7% below fair value)
Industry Position: 50.6% below the Drug Manufacturers median (#138 of 923)
No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score
Get the complete analysis for HKSE:02161
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02161 has been successfully added to your 
